• Capstone posted Q2 2026 net sales of USD 21.5 million, up 67% year over year.
• Gross profit climbed to USD 6 million, up 92%, lifting gross margin by 3.5 percentage points to 27.9%.
• Operating results swung to income of USD 432,000 from a loss a year earlier.
• Stone Business Adjusted EBITDA (non-GAAP) rose to USD 2 million, more than doubled, with margin improving to 9.4%.
• Reaffirmed full-year targets of USD 72.1 million revenue, USD 18.7 million gross profit, USD 3.8 million Stone Business Adjusted EBITDA (non-GAAP).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.